New York State Common Retirement Fund Sells 22,752 Shares of Catalent, Inc. (NYSE:CTLT)

New York State Common Retirement Fund lessened its position in shares of Catalent, Inc. (NYSE:CTLT - Free Report) by 4.4% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 488,965 shares of the company's stock after selling 22,752 shares during the period. New York State Common Retirement Fund owned approximately 0.27% of Catalent worth $21,969,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Thompson Siegel & Walmsley LLC increased its holdings in Catalent by 46.6% during the 3rd quarter. Thompson Siegel & Walmsley LLC now owns 704,322 shares of the company's stock worth $32,069,000 after acquiring an additional 223,944 shares during the period. Vanguard Group Inc. increased its holdings in Catalent by 1.8% during the 3rd quarter. Vanguard Group Inc. now owns 20,468,027 shares of the company's stock worth $931,909,000 after acquiring an additional 365,648 shares during the period. Tran Capital Management L.P. increased its holdings in Catalent by 12.2% during the 4th quarter. Tran Capital Management L.P. now owns 361,846 shares of the company's stock worth $16,258,000 after acquiring an additional 39,208 shares during the period. Hsbc Holdings PLC increased its holdings in Catalent by 43.1% during the 3rd quarter. Hsbc Holdings PLC now owns 193,322 shares of the company's stock worth $8,803,000 after acquiring an additional 58,240 shares during the period. Finally, SG Americas Securities LLC increased its holdings in Catalent by 240.0% during the 4th quarter. SG Americas Securities LLC now owns 40,249 shares of the company's stock worth $1,808,000 after acquiring an additional 28,410 shares during the period.

Analysts Set New Price Targets

A number of equities analysts have recently commented on the stock. Stephens reissued an "equal weight" rating and issued a $63.50 price target on shares of Catalent in a report on Thursday, April 4th. Royal Bank of Canada reissued a "sector perform" rating and issued a $63.50 price target on shares of Catalent in a report on Tuesday, February 20th. StockNews.com assumed coverage on shares of Catalent in a report on Saturday. They issued a "sell" rating on the stock. UBS Group reissued a "neutral" rating and issued a $63.50 price target (up previously from $58.00) on shares of Catalent in a report on Tuesday, February 6th. Finally, Barclays increased their price target on shares of Catalent from $45.00 to $47.00 and gave the stock an "equal weight" rating in a report on Thursday, January 25th. Two investment analysts have rated the stock with a sell rating, nine have issued a hold rating and three have assigned a buy rating to the stock. According to MarketBeat, Catalent has a consensus rating of "Hold" and an average price target of $52.46.

Catalent Trading Up 0.2 %

Shares of Catalent stock traded up $0.12 during trading on Friday, reaching $55.92. The company's stock had a trading volume of 2,846,393 shares, compared to its average volume of 1,545,863. Catalent, Inc. has a 52-week low of $31.45 and a 52-week high of $60.20. The company has a market cap of $10.12 billion, a price-to-earnings ratio of -8.22, a PEG ratio of 6.03 and a beta of 1.20. The firm's 50-day moving average is $56.68 and its two-hundred day moving average is $48.70. The company has a quick ratio of 1.73, a current ratio of 2.48 and a debt-to-equity ratio of 1.34.

Catalent (NYSE:CTLT - Get Free Report) last announced its quarterly earnings results on Friday, February 9th. The company reported ($0.24) earnings per share for the quarter, missing the consensus estimate of ($0.02) by ($0.22). The firm had revenue of $1.03 billion for the quarter, compared to analysts' expectations of $1.01 billion. Catalent had a negative net margin of 29.91% and a negative return on equity of 2.43%. The company's quarterly revenue was down 10.2% on a year-over-year basis. During the same period in the previous year, the company earned $0.62 EPS. On average, sell-side analysts anticipate that Catalent, Inc. will post 0.28 earnings per share for the current year.

Catalent Company Profile

Catalent, Inc, together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates in two segments, Biologics, and Pharma and Consumer Health. The Biologics segment provides formulation, development, and manufacturing for biologic proteins, cell gene, and other nucleic acid therapies; pDNA, iPSCs, oncolytic viruses, and vaccines; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, and cartridges; and analytical development and testing services for large molecules.